Currently out of the existing stock ratings of Andrea Tan, 57 are a BUY (63.33%), 27 are a HOLD (30%), 6 are a SELL (6.67%).

Andrea Tan

Work Performance Price Targets & Ratings Chart

Analyst Andrea Tan, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 58.88% that have a potential upside of 51.69% achieved within 183 days.

Andrea Tan’s has documented 171 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on INSM, Insmed at 24-Sep-2026.

Wall Street Analyst Andrea Tan

Analyst best performing recommendations are on CDAK (CODIAK BIOSCIENCES).
The best stock recommendation documented was for CDAK (CODIAK BIOSCIENCES) at 8/31/2022. The price target of $2 was fulfilled within 1 day with a profit of $0.15 (6.98%) receiving and performance score of 69.77.

Average potential price target upside

CDAK Codiak BioSciences DAWN Day One Biopharmaceuticals FATE Fate Therapeutics INSM Insmed MDGL Madrigal Pharmaceuticals RLMD Relmada Therapeutics ABCL Abcellera Biologics CNTA Centessa Pharmaceuticals PLC ADR IOVA Iovance Biotherapeutics TARS Tarsus Pharmaceuticals SGMT Sagimet Biosciences Series A Common Stock ARWR Arrowhead Pharmaceuticals KOD Kodiak Sciences KRYS Krystal Biotech CD Chindata Group Holdings Ltd ALKS Alkermes Plc ETNB 89bio RVMD Revolution Medicines SDGR Schrodinger

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 07-Nov-2022

$1.4

$1.39 (13900.00%)

3 years 11 months 9 days ago
(07-Nov-2022)

0/2 (0%)

$0.6 (75.00%)

Buy Since 09-Nov-2020

$34

4 years 7 months 24 days ago
(22-Feb-2022)

2/4 (50%)

$21.8 (178.69%)

15

Show more analysts

Please expand the browser size to see the chart

Which stock is Andrea Tan most bullish on?

Potential upside of $232.25 has been obtained for MDGL (MADRIGAL PHARMACEUTICALS)

Which stock is Andrea Tan most reserved on?

Potential downside of -$63.87 has been obtained for KOD (KODIAK SCIENCES)

What Year was the first public recommendation made by Andrea Tan?

On 2019
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?